CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
1.090
+0.050 (4.81%)
At close: Apr 25, 2025, 4:00 PM
1.120
+0.030 (2.75%)
After-hours: Apr 25, 2025, 6:54 PM EDT
CNS Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for CNS Pharmaceuticals.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for CNS Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 25, 2025 |
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $25 | Hold → Strong Buy | Upgrades | $25 | +2,193.58% | Sep 10, 2024 |
Brookline Capital | Brookline Capital | Strong Buy Initiates $750,000 | Strong Buy | Initiates | $750,000 | +68,807,239.45% | Feb 2, 2021 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $825,000 | Strong Buy | Initiates | $825,000 | +75,687,973.39% | Aug 24, 2020 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-42.97
from -38.87
EPS Next Year
-1.64
from -42.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | n/a | n/a | 38.8M |
Avg | n/a | n/a | 37.7M |
Low | n/a | n/a | 36.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -44.24 | -1.69 | -1.91 |
Avg | -42.97 | -1.64 | -1.86 |
Low | -41.29 | -1.58 | -1.78 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.